- Home
- ESPR vs BGH Comparison
ESPR vs BGH Comparison
Compare ESPR & BGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ESPR | BGH |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 898.5M | 297.0M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | ESPR | BGH |
|---|---|---|
| Price | $3.66 | $15.15 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $6.86 | N/A |
| AVG Volume (30 Days) | ★ 6.4M | 61.5K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.06% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $303,802,000.00 | N/A |
| Revenue This Year | $25.45 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.83 | N/A |
| 52 Week Low | $0.69 | $11.92 |
| 52 Week High | $4.13 | $14.50 |
Technical Indicators
Market Signals| Indicator | ESPR | BGH |
|---|---|---|
| Relative Strength Index (RSI) | 53.96 | 52.46 |
| Support Level | $3.72 | $14.99 |
| Resistance Level | $4.13 | $15.35 |
| Average True Range (ATR) | 0.22 | 0.13 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 10.19 | 47.22 |
Price Performance
Historical ComparisonAbout ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About BGH Barings Global Short Duration High Yield Fund of Beneficial Interests
Barings Global Short Duration High Yield Fund is a diversified, closed-end management investment company. Its investment objective is to seek as high a level of current income as the Adviser determines is consistent with capital preservation.